Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

TNGX 12.03.2024

Full Press ReleaseSEC FilingsOur TNGX Tweets

About Gravity Analytica

Recent News

  • 12.05.2024 - Piper Sandler 36th Annual Healthcare Conference
  • 12.03.2024 - Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • 11.27.2024 - Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference

Recent Filings

  • 01.13.2025 - 8-K Current report
  • 01.13.2025 - EX-99.1 EX-99.1
  • 01.02.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
PDF Version

BOSTON--(BUSINESS WIRE)--Dec. 3, 2024--Tango Therapeutics, Inc.(NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that, effectiveDecember 2, 2024, the Compensation Committee ofTango Therapeutics'Board of Directors granted a non-qualified stock option to purchase 187,500 shares of its common stock and 31,250 restricted stock units (RSUs) to a new employee underTango Therapeutics'2023 Inducement Plan.

TheTango Therapeutics2023 Inducement Plan is used exclusively for the grant of equity awards to individuals as an inducement material to such individual's entering into employment withTango Therapeutics, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.

The options have an exercise price of$3.89per share, which is equal to the closing price ofTango Therapeutics'common stock onDecember 2, 2024. Each option will vest as to 25% of the shares underlying such option onNovember 18, 2025and as to an additional 1/36th of the remaining shares underlying the option monthly thereafter, in each case, subject to such employee's continued employment on each vesting date. The RSU award will vest as to: (i) 10,416 shares on or aboutNovember 12, 2025, (ii) 10,417 shares on or aboutNovember 9, 2026, and (iii) 10,417 shares on or aboutNovember 8, 2027, subject to such employee's continued employment on each vesting date. The options and RSUs are subject to the terms and conditions ofTango Therapeutics'2023 Inducement Plan, which was approved inFebruary 2023, and the terms and conditions of the stock option and RSU agreements covering the grant.

AboutTango Therapeutics

Tango Therapeuticsis a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing. For more information, please visitwww.tangotx.com.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241203268375/en/

Investor:Sam Martin/Andrew VulisArgot Partnerstango@argotpartners.com

Media:Amanda Brown GalgaySVP, Corporate Communications,Tango Therapeuticsmedia@tangotx.com

Source:Tango Therapeutics, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com